CR20230517A - Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades - Google Patents
Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedadesInfo
- Publication number
- CR20230517A CR20230517A CR20230517A CR20230517A CR20230517A CR 20230517 A CR20230517 A CR 20230517A CR 20230517 A CR20230517 A CR 20230517A CR 20230517 A CR20230517 A CR 20230517A CR 20230517 A CR20230517 A CR 20230517A
- Authority
- CR
- Costa Rica
- Prior art keywords
- chromenone
- phosphoinositide
- allosteric
- pi3k
- kinase
- Prior art date
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title 2
- 108091007960 PI3Ks Proteins 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La descripción se relaciona con los compuestos de la Fórmula (I) como inhibidores alostéricos de cromenona del fosfoinositido 3-quinasa (PI3K) útiles en el tratamiento de enfermedades o trastornos asociados con la modulación de PI3K, la Fórmula (I): (I) o sales farmacéuticamente aceptables de estos, en donde <strong>R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, </strong>y <strong>R<sub>8</sub></strong>, son como se definen en la presente descripción. La descripción también se refiere a métodos para preparar y usar los compuestos de Fórmula (I) o sales farmacéuticamente aceptables de estos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183355P | 2021-05-03 | 2021-05-03 | |
| US202163227526P | 2021-07-30 | 2021-07-30 | |
| US202163250530P | 2021-09-30 | 2021-09-30 | |
| US202163253232P | 2021-10-07 | 2021-10-07 | |
| PCT/US2022/027304 WO2022235574A1 (en) | 2021-05-03 | 2022-05-02 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230517A true CR20230517A (es) | 2023-11-28 |
Family
ID=81749155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230517A CR20230517A (es) | 2021-05-03 | 2022-05-02 | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11873295B2 (es) |
| EP (1) | EP4333984A1 (es) |
| JP (1) | JP7308369B2 (es) |
| KR (1) | KR20240004865A (es) |
| AU (1) | AU2022268900A1 (es) |
| BR (1) | BR112023022940A2 (es) |
| CA (1) | CA3217937A1 (es) |
| CO (1) | CO2023015037A2 (es) |
| CR (1) | CR20230517A (es) |
| DO (1) | DOP2023000245A (es) |
| EC (1) | ECSP23083562A (es) |
| IL (1) | IL307950A (es) |
| TW (1) | TW202309003A (es) |
| WO (1) | WO2022235574A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015134326A1 (en) | 2014-03-03 | 2015-09-11 | Intercontinental Great Brands Llc | Method for manufacturing a comestible |
| TWI829179B (zh) | 2021-05-27 | 2024-01-11 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| TW202329930A (zh) * | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| US20240018115A1 (en) * | 2022-04-29 | 2024-01-18 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| CN117362281A (zh) * | 2022-07-07 | 2024-01-09 | 海创药业股份有限公司 | 一种pi3k抑制剂及其制备方法和用途 |
| JP2024067010A (ja) * | 2022-11-02 | 2024-05-16 | ペトラ・ファーマ・コーポレイション | 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 |
| JP2024067008A (ja) * | 2022-11-02 | 2024-05-16 | ペトラ・ファーマ・コーポレイション | 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 |
| WO2024097721A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1190405B (it) | 1985-10-22 | 1988-02-16 | Recordati Chem Pharm | Derivati del flavone |
| IL89840A (en) | 1988-04-06 | 1996-10-31 | Lipha | Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them |
| HUT58310A (en) | 1988-12-21 | 1992-02-28 | Upjohn Co | Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1257537B1 (en) | 2000-01-24 | 2007-05-30 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| JP4646626B2 (ja) | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| JP2011510071A (ja) | 2008-01-25 | 2011-03-31 | アストラゼネカ アクチボラグ | 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６ |
| US8513221B2 (en) * | 2008-07-07 | 2013-08-20 | Xcovery Holding, LLC | PI3K isoform selective inhibitors |
| US9326986B2 (en) | 2008-09-29 | 2016-05-03 | Glaxosmithkline Llc | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| MX2018010993A (es) | 2016-03-11 | 2019-01-17 | H Lee Moffitt Cancer Ct & Res | Derivados de icariina e icaritina. |
| CN108299365B (zh) | 2018-01-31 | 2021-08-06 | 中南大学 | 一种黄酮衍生物及其应用 |
| AR121719A1 (es) | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| WO2021226677A1 (en) | 2020-05-14 | 2021-11-18 | The Heart Research Institute Ltd | Treatment of thrombosis and associated disorders with an anti-platelet agent. |
| IL304895A (en) | 2021-02-01 | 2023-10-01 | Geode Therapeutics Inc | INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment |
| AU2022269566A1 (en) | 2021-05-03 | 2023-11-02 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| TWI829179B (zh) | 2021-05-27 | 2024-01-11 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| WO2023060262A1 (en) | 2021-10-07 | 2023-04-13 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
| WO2023081209A1 (en) | 2021-11-03 | 2023-05-11 | Zeno Management, Inc. | Pi3k inhibitors and methods of treating cancer |
| WO2023078401A1 (en) | 2021-11-05 | 2023-05-11 | Fochon Biosciences, Ltd. | Compounds as protein kinase inhibitors |
| WO2023104111A1 (en) | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
-
2022
- 2022-05-02 AU AU2022268900A patent/AU2022268900A1/en active Pending
- 2022-05-02 IL IL307950A patent/IL307950A/en unknown
- 2022-05-02 JP JP2022576847A patent/JP7308369B2/ja active Active
- 2022-05-02 CR CR20230517A patent/CR20230517A/es unknown
- 2022-05-02 WO PCT/US2022/027304 patent/WO2022235574A1/en active Application Filing
- 2022-05-02 EP EP22724582.6A patent/EP4333984A1/en active Pending
- 2022-05-02 BR BR112023022940A patent/BR112023022940A2/pt unknown
- 2022-05-02 CA CA3217937A patent/CA3217937A1/en active Pending
- 2022-05-02 US US17/734,705 patent/US11873295B2/en active Active
- 2022-05-02 TW TW111116590A patent/TW202309003A/zh unknown
- 2022-05-02 KR KR1020237041572A patent/KR20240004865A/ko active Search and Examination
-
2023
- 2023-10-13 US US18/486,620 patent/US20240051948A1/en active Pending
- 2023-11-01 EC ECSENADI202383562A patent/ECSP23083562A/es unknown
- 2023-11-03 CO CONC2023/0015037A patent/CO2023015037A2/es unknown
- 2023-11-03 DO DO2023000245A patent/DOP2023000245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL307950A (en) | 2023-12-01 |
| WO2022235574A1 (en) | 2022-11-10 |
| US20230017140A1 (en) | 2023-01-19 |
| TW202309003A (zh) | 2023-03-01 |
| JP7308369B2 (ja) | 2023-07-13 |
| AU2022268900A1 (en) | 2023-11-16 |
| DOP2023000245A (es) | 2024-01-31 |
| US20240051948A1 (en) | 2024-02-15 |
| KR20240004865A (ko) | 2024-01-11 |
| BR112023022940A2 (pt) | 2024-01-23 |
| CO2023015037A2 (es) | 2023-11-20 |
| ECSP23083562A (es) | 2024-02-29 |
| EP4333984A1 (en) | 2024-03-13 |
| CA3217937A1 (en) | 2022-11-10 |
| JP2023523095A (ja) | 2023-06-01 |
| US11873295B2 (en) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230517A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| MX2022012306A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| IL308191A (en) | Allosteric chromanone inhibitors of PHOSPHOINOSITIDE 3-KINASE (PI3K) for the treatment of diseases | |
| MX2009005925A (es) | Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso. | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| MX2008013583A (es) | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. | |
| EA201101435A1 (ru) | Имидазотиадиазолы для применения в качестве ингибиторов киназ | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| EA201992354A1 (ru) | Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона | |
| EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
| NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| BR112023022890A2 (pt) | Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| ZA202109193B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| UA98946C2 (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use |